



ALLIA.143A

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

|           |   |                                   |   |  |
|-----------|---|-----------------------------------|---|--|
| Applicant | : | Zaghouani, H.                     | ) | Group Art Unit 1644                            |
|           |   |                                   | ) |  |
| Appl. No. | : | 09/779,767                        | ) | I hereby certify that this correspondence and  |
|           |   |                                   | ) | all marked attachments are being deposited     |
| Filed     | : | January 7, 1997                   | ) | with the United States Postal Service as first |
|           |   |                                   | ) | class mail in an envelope addressed to:        |
| For       | : | Compounds, Compositions and       | ) | Commissioner of Patents and Trademarks,        |
|           |   | Methods for the Endocytic         | ) | Washington, D.C. 20231, on                     |
|           |   | Presentation of Immunosuppressive | ) |  |
|           |   | Factors                           | ) | <u>12/19/2002</u>                              |
|           |   |                                   | ) | <u>Christine Hughey</u>                        |
| Examiner  | : | P. Nolan                          | ) | Christine Hughey                               |
|           |   |                                   | ) |  |

**AMENDMENT AND RESPONSE TO OFFICE ACTION**

United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Dear Sir:

In response to the Office Action dated October 21, 2002, applicant submits the following response:

**In the Claims:**

Please amend claim 66 as follows:

66. (Six times amended) A composition comprising an immunoglobulin or a portion thereof linked to a protein fragment or peptide, wherein said immunoglobulin or portion thereof is capable of binding to an Fc receptor and said protein fragment or peptide comprises a T cell receptor antagonist, said composition having the property of being endocytosed by cells bearing said Fc receptor and processed by the cells to present said T cell receptor antagonist in association with endogenous MHC Class II molecules, thereby preventing activation of autoreactive T cells *in vivo*.

RECEIVED  
APR 21 2003  
TECH CENTER 1600/2900